Who is eligible for clinical trial NCT07157787?

Participants must meet protocol criteria for Primary Membranous Nephropathy. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07157787 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) (NCT07157787)

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants With PMN (Primary Membranous Nephropathy) Who Are at a High Risk for Disease Progression

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

Who can join: Review the eligibility criteria below.

Location: Research Site — Loma Linda, California

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

Research Site — Loma Linda, California
Research Site — San Diego, California
Research Site — Minneapolis, Minnesota
Research Site — Rochester, Minnesota
Research Site — Houston, Texas
Research Site — Buenos Aires,
Research Site — CABA,
Research Site — Ciudad de Buenos Aires,
Research Site — La Plata,
Research Site — Rosario,
Research Site — Santa Fe,
Research Site — Santa Fe,
Research Site — Gosford,
Research Site — Parkville,
Research Site — Southport,
Research Site — Recife,
Research Site — Salvador,
Research Site — São Paulo,
Research Site — São Paulo,
Research Site — Baotou,
Research Site — Beijing,
Research Site — Guangzhou,
Research Site — Shenzhen,
Research Site — Créteil,
Research Site — Nice,

📞 Contact the Study Coordinator

Phone: (855) 752-2356

Email: clinicaltrials@alexion.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Membranous Nephropathy

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Granada Hills, California
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — San Francisco, California
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Montgomery, Alabama
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Huntsville, Alabama
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy — Denver, Colorado

Explore by condition: All Primary Membranous Nephropathy clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗